Хроническая спонтанная крапивница: диагностические и прогностические маркеры


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Хроническая спонтанная крапивница (ХСК) - заболевание, связанное с дегрануляцией тучных клеток и появлением волдырей, зуда и (или) ангиоотеков в течение >6 нед при отсутствии специфических триггеров. Медико-социальное значение ХСК обусловлено широкой распространенностью, развитием преимущественно у лиц трудоспособного возраста, выраженным снижением качества жизни пациентов и высоким уровнем затрат на лечение. Иммунопатогенетические механизмы развития ХСК могут существенно варьировать у разных больных. Поиск новых клинических и лабораторных маркеров ХСК, способных помочь определить лучший терапевтический подход, отследить изменения в активности заболевания, предсказать ответ на терапию, является актуальной задачей современной медицины.

Полный текст

Доступ закрыт

Об авторах

Е. В Бурыгина

Северо-Западный государственный медицинский университет им. И.И. Мечникова

Санкт-Петербург

Я. И Козлова

Северо-Западный государственный медицинский университет им. И.И. Мечникова

кандидат медицинских наук Санкт-Петербург

Н. Н Климко

Северо-Западный государственный медицинский университет им. И.И. Мечникова

доктор медицинских наук, профессор Санкт-Петербург

Список литературы

  1. Zuberbier T., Aberer W., Asero R. et al. The EAACI/GA2LEN/EDF/ WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy Eur J Allergy Clin Immunol. 2018; 73: 1393-414. doi: 10.1111/all.13397
  2. Данилычева И.В. Новый европейский согласительный документ по диагностике и ведению хронической крапивницы. Что нового? Российский аллергологический журнал. 2018; 15 (4): 54-61
  3. Lee N., Lee J.D., Lee H.Y. et al. Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014. Allergy Asthma Immunol Res. 2017; 9 (5): 438-45. doi: 10.4168/aair.2017.9.5.438
  4. Colgecen E., Kemal O., Gul A.I. et al. Evaluation of Etiological Factors in Patients with Chronic Urticaria. Acta Dermatovenerol Croat. 2015; 23 (1): 36-42.
  5. Kolkhir P., Church M.K., Weller K. et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017; 139: 1772-81.e1. doi: 10.1016/j.jaci.2016.08.050
  6. Curto-Barredo L., Archilla L.R., Vives G.R. et al. Clinical Features of Chronic Spontaneous Urticaria that Predict Disease Prognosis and Refractoriness to Standard Treatment. Acta Derm Venereol. 2018; 98 (7): 641-7. doi: 10.2340/00015555-2941
  7. Schmetzer O., Lakin E., Topal F.A. et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018; 142: 876-82. DOI: 10.10 16/j.jaci.2017.10.035
  8. Puxeddu I., Petrelli F., Angelotti F. et al. Biomarkers In Chronic Spontaneous Urticaria: Current Targets And Clinical Implications. J Asthma Allergy. 2019; 12: 285-95. doi: 10.2147/JAA.S184986
  9. Stull D., McBride D., Tian H. et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol. 2017; 177: 1093-101. doi: 10.1111/bjd.15454
  10. Sanchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A. et al. Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. J Eur Acad Dermatology Venereol. 2017; 31 (6): 964-97. doi: 10.1111/jdv.14221
  11. Amsler E., Augey F., Soria A.et al. Chronic urticaria and hormones: is there a link? J Eur Acad Dermatol Venereol. 2016; 30 (9): 1527-30. DOI: 10.1111/ jdv.13644
  12. Hiragun M., Hiragun T., Mihara S. et al. Prognosis of chronic spontaneous urticaria in 117 patients not controlled by a standard dose of antihistamine. Allergy Eur J Allergy Clin Immunol. 2013; 68 (2): 229-35. doi: 10.1111/all.12078
  13. Sanchez-Borges M., Caballero-Fonseca F., Capriles-Hulett A. et al. Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2015; 29 (4): 698-701. doi: 10.1111/jdv.12658
  14. Sanchez-Borges M., Tassinari S., Flores A. Epidemiologic features in patients with antihistamine-resistant chronic urticaria. RevAlerg Mex. 2015; 62 (4): 279-86.
  15. Metz M., Gimenez-Arnau A., Borzova E. et al. Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. Allergy Clin Immunol. 2009; 123: 705-6. DOI: 10.1016/j. jaci.2008.11.040
  16. Mosquera L., Milena K., Moya Camacho B. et al. The Autologous Serum Skin Test as a Prognostic Factor for the Severity and Duration of Chronic Urticaria after five years of Follow-up. J Allergy Clin Immunol. 2018; 141 (2): AB46.
  17. Grattan C., Dawn G., Gibbs S. et al. Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity. Clin Exp Allergy. 2003; 33: 337 doi: 10.1046/j.1365-2222.2003.01589.x
  18. Kolkhir P., Church M.K., Altrichter S. et al. Eosinopenia in Chronic Spontaneous Urticaria Is Associated with High Disease Activity, Autoimmunity and Poor Response to Treatment. J Allergy Clin Immunol Pract. 2020; 8 (1): 318-25.e5. doi: 10.1016/j.jaip.2019.08.025
  19. Rorsman H. Basopenia in urticaria. Acta Allergol. 1961; 16: 185-215. doi: 10.1111/j.1398-9995.1961.tb02894.x
  20. Rauber M.M., Pickert J., Holiangu L. et al. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria. Allergy. 2017; 72: 1904-11. doi: 10.1111/all.13215
  21. Magen E., Mishal J., Zeldin Y. et al. Increased mean platelet volume and C-reactive protein levels in patients with chronic urticaria with a positive autologous serum skin test. Am J Med Sci. 2010; 339: 504-8. DOI: 10.1097/ MAJ.0b013e3181db6ed5
  22. Kolkhir P., Andre F., Church M.K. et al. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2017; 47: 19-36. DOI: 10.1111/ cea.12870
  23. Tedeschi A., Asero R., Lorini M. et al. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy. 2010; 40: 875-81. doi: 10.1111/j.1365-2222.2010.03473.x
  24. Kolkhir P., Altrichter S., Hawro T. et al. C-reactive protein is linked to disease activity, impact, and response to treatment in patients with chronic spontaneous urticaria. Allergy Eur J Allergy Clin Immunol. 2018; 73 (4): 940-8. doi: 10.1111/all.13352
  25. Asero R. Severe CSU and activation of the coagulation/fibrinolysis system: clinical aspects. Eur Ann Allergy Clin Immunol. 2019; 52 (1): 15-7. DOI: 10.23822/ EurAnnACI.1764-1489.109
  26. Kasperska-Zajac A., Grzanka A., Damasiewicz-Bodzek A. IL-6 transsignaling in patients with chronic spontaneous urticaria. PLoS One. 2015; 10 (12): e0145751. doi: 10.1371/journal.pone.0145751
  27. Puxeddu I., Italiani P., Giungato P. et al. Free IL-18 and IL-33 cytokines in chronic spontaneous urticaria. Cytokine. 2013; 61 (3): 741-3. DOI: 10.1016/j. cyto.2013.01.015
  28. Atwa M.A., Emara A.S., Youssef N. et al. Serum concentration of IL-17, IL-23 and TNF-а among patients with chronic spontaneous urticaria: association with disease activity and autologous serum skin test. J Eur Acad Dermatol Venereol. 2014; 28 (4): 469-74. doi: 10.1111/jdv.12124
  29. Raap U., Wieczorek D., Gehring M. et al. Increased levels of serum IL-31 in chronic spontaneous urticaria. Exp Dermatol. 2010; 19 (5): 464-6. doi: 10.1111/j.1600-0625.2010.01067.x
  30. Bae Y., Kang S.H., Park J.O. et al. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria. Allergol Int. 2019; 69 (2): 304-6. DOI: 10.1016/j. alit.2019.10.009 [Online ahead of print]
  31. Ye Y.M., Yang E.M., Yoo H.S. et al. Increased level of basophil CD203c expression predicts severe chronic urticaria. J Korean Med Sci. 2014; 29: 43. doi: 10.3346/jkms.2014.29.1.43
  32. Woo Y.R., Jung K.E., Koo D.W. et al. Vitamin D as a marker for disease severity in chronic urticaria and its possible role in pathogenesis. Ann Dermatol. 2015; 27: 423. doi: 10.5021/ad.2015.27.4.423
  33. Trinh H.K.T., Le P.D., Ban G.Y. et al. Altered systemic adipokines in patients with chronic urticaria. Int Arch Allergy Immunol. 2016; 171 (2): 102-10. doi: 10.1159/000452626
  34. Huilan Z., Bihua L., Runxiang L. et al. Features of antihistamine-resistant chronic urticaria and chronic urticaria during exacerbation. Indian J Dermatol. 2015; 60: 323. doi: 10.4103/0019-5154.156458
  35. Belot V., Desbois I., Martin L. et al. Assessment of the usefulness of autologous serum skin testing in chronic urticaria: A retrospective single-centre study of 74 patients. Ann Dermatol Venereol. 2010; 137: 444-50. DOI: 10.1016/j. annder.2010.04.014
  36. Kolkhir P., Pogorelov D., Olisova O. CRP, D-Dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria. Eur Ann Allergy Clin Immunol. 2017; 49 (4): 18992. doi: 10.23822/EurAnnACI.1764-1489.05
  37. Gericke J., Metz M., Ohanyan T. et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2016; 4: 529-30. doi: 10.1016/j.jaci.2016.07.047
  38. Straesser M.D., Oliver E., Palacios T. et al. Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2018; 6: 1386-8. DOI: 10.1016/j. jaip.2017.10.030
  39. Weller K., Ohanyan T., Hawro T. et al. Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. Allergy Eur J Allergy Clin Immunol. 2018; 73: 2406-8. doi: 10.1111/all.13586
  40. Asero R., Marzano A.V., Ferrucci S. et al. D-Dimer plasma levels parallel the clinical response to omalizumab in patients with severe chronic spontaneous urticaria. Int Arch Allergy Immunol. 2017; 172: 40-4. doi: 10.1159/000453453
  41. Altrichter S., Hawro T., Hanel K. et al. Successful omalizumab treatment in chronic spontaneous urticaria is associated with lowering of serum IL-31 levels. J Eur Acad Dermatology Venereol. 2016; 30 (3): 454-5. doi: 10.1111/jdv.12831
  42. Deza G., Bertolin-Colilla M., Pujol R.M. et al. Basophil FceR1 expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy. Acta Derm Venereol. 2017; 97: 698-704. doi: 10.2340/00015555-2654
  43. Metz M., Staubach P., Bauer A. et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FceRI-positive cells in the skin. Theranostics. 2017; 7: 1266-76. doi: 10.7150/thno.18304
  44. Palacios T., Stillman L., Borish L. et al. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria. J Allergy Clin Immunol Pract. 2016; 4: 529-30. doi: 10.1016/j.jaip.2015.11.025
  45. Erta§ R., Hawro T., Altrichter S. et al. Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU. Allergy. 2019; 75 (2): 468-70. doi: 10.1111/all.14033. [Online ahead of print]
  46. Kulthanan K., Subchookul C., Hunnangkul S. et al. Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria: A Systematic Review. Allergy Asthma Immunol Res. 2019; 11 (5): 73655. doi: 10.4168/aair.2019.11.5.736
  47. Iqbal K., Bhargava K., Skov P.S. et al. A positive serum basophil histamine release assay is a marker for cyclosporine responsiveness in patients with chronic spontaneous urticarial. Clin Transl Allergy. 2012; 2: 19. doi: 10.1186/2045-7022 2-19
  48. Baek Y.S., Jeon J., Kim J.H. et al. Severity of acute and chronic urticaria correlates with D-dimer level, but not C-reactive protein or total IgE. Clin Exp Dermatol. 2014; 39: 795-800. doi: 10.1111/ced.12413
  49. Asero R. Plasma D-dimer levels and clinical response to cyclosporine in severe chronic spontaneous urticaria. J Allergy Clin Immunol. 2015; 135: 1401-3. doi: 10.1016/j.jaci.2014.11.016
  50. Santiago L., Ferreira B., Ramos L. et al. IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria. Br J Dermatol. 2019; 180: 199-200. doi: 10.1111/bjd.17005

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах